Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.
Akbar K WaljeeB LiuK SauderJ ZhuS M GovaniRyan William StidhamPeter D R HigginsPublished in: Alimentary pharmacology & therapeutics (2018)
A machine learning algorithm using laboratory data through week 6 of vedolizumab therapy was able to accurately identify which UC patients would achieve corticosteroid-free endoscopic remission on vedolizumab at week 52. Application of this algorithm could have significant implications for clinical decisions on whom to continue on this costly medication when the benefits of the vedolizumab are not clinically apparent in the first 6 weeks of therapy.
Keyphrases
- ulcerative colitis
- machine learning
- deep learning
- big data
- ultrasound guided
- end stage renal disease
- ejection fraction
- newly diagnosed
- patients with inflammatory bowel disease
- artificial intelligence
- healthcare
- prognostic factors
- randomized controlled trial
- magnetic resonance
- clinical trial
- patient reported outcomes
- bone marrow
- systemic lupus erythematosus
- study protocol
- endoscopic submucosal dissection